EGFR and non-small cell lung carcinoma: Wan et al. (2020) further investigated its role in cardiotoxicity and its potential as a therapeutic target in cancer physiology.36 Moreover, Occhipinti M. et al. also reported that statin use was negatively correlated with progression-free survival in stage IV advanced NSCLC patients receiving EGFR-TKIs (p= 0.02; HR 0.281, 95% CI: 0.096–0.825), indicating a detrimental drug interaction between statins and TKIs.37